CN113166270A - 融合蛋白及其应用 - Google Patents
融合蛋白及其应用 Download PDFInfo
- Publication number
- CN113166270A CN113166270A CN201880099747.3A CN201880099747A CN113166270A CN 113166270 A CN113166270 A CN 113166270A CN 201880099747 A CN201880099747 A CN 201880099747A CN 113166270 A CN113166270 A CN 113166270A
- Authority
- CN
- China
- Prior art keywords
- fusion protein
- fragment
- construct
- protein
- sequencing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 81
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 81
- 238000000034 method Methods 0.000 claims abstract description 51
- 239000012634 fragment Substances 0.000 claims abstract description 48
- 108010061982 DNA Ligases Proteins 0.000 claims abstract description 43
- 102000012410 DNA Ligases Human genes 0.000 claims abstract description 41
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 29
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 26
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 26
- 230000004568 DNA-binding Effects 0.000 claims abstract description 12
- 230000000694 effects Effects 0.000 claims abstract description 6
- 238000012163 sequencing technique Methods 0.000 claims description 73
- 238000010276 construction Methods 0.000 claims description 49
- 238000000746 purification Methods 0.000 claims description 31
- 210000004027 cell Anatomy 0.000 claims description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 11
- 229930027917 kanamycin Natural products 0.000 claims description 9
- 229960000318 kanamycin Drugs 0.000 claims description 9
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 9
- 229930182823 kanamycin A Natural products 0.000 claims description 9
- 239000013612 plasmid Substances 0.000 claims description 9
- 230000004952 protein activity Effects 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 102000052510 DNA-Binding Proteins Human genes 0.000 claims description 4
- 101710096438 DNA-binding protein Proteins 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 3
- 229960000723 ampicillin Drugs 0.000 claims description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 3
- 210000004507 artificial chromosome Anatomy 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 description 47
- 229920001223 polyethylene glycol Polymers 0.000 description 47
- 239000000654 additive Substances 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 23
- 230000008569 process Effects 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 108010006401 NF-kappa B p50 Subunit Proteins 0.000 description 13
- 102000005395 NF-kappa B p50 Subunit Human genes 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 108091008324 binding proteins Proteins 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 102000014914 Carrier Proteins Human genes 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 101710163270 Nuclease Proteins 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108010067770 Endopeptidase K Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108091092584 GDNA Proteins 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000205091 Sulfolobus solfataricus Species 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- 239000006167 equilibration buffer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000007500 overflow downdraw method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 101710180319 Protease 1 Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 101710137710 Thioesterase 1/protease 1/lysophospholipase L1 Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- -1 etc. Proteins 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000007169 ligase reaction Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
提出了融合蛋白及其获得方法和应用、分离的核酸分子、构建体以及重组细胞，所述融合蛋白包括：第一片段，所述第一片段具有T4DNA连接酶活性；以及第二片段，所述第一片段的一端与所述第二片段的一端相连，所述第二片段具有DNA结合结构域。
Description
PCT国内申请，说明书已公开。
Claims (18)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/121545 WO2020124319A1 (zh) | 2018-12-17 | 2018-12-17 | 融合蛋白及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113166270A true CN113166270A (zh) | 2021-07-23 |
Family
ID=71100173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880099747.3A Pending CN113166270A (zh) | 2018-12-17 | 2018-12-17 | 融合蛋白及其应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113166270A (zh) |
| WO (1) | WO2020124319A1 (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115896047A (zh) * | 2022-12-12 | 2023-04-04 | 南京诺唯赞生物科技股份有限公司 | 重组t4 dna连接酶突变体、融合蛋白及其应用 |
| CN116004681A (zh) * | 2022-08-15 | 2023-04-25 | 南京诺唯赞生物科技股份有限公司 | 一种提高topo克隆中载体连接效率的方法及试剂盒 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113774032B (zh) * | 2021-11-12 | 2022-03-01 | 翌圣生物科技(上海)股份有限公司 | 重组t4连接酶突变体、编码dna及ngs建库方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102597006A (zh) * | 2009-09-16 | 2012-07-18 | 梅西大学 | 融合多肽以及其应用 |
| US20140273102A1 (en) * | 2013-03-15 | 2014-09-18 | Theranos, Inc. | Thermostable blunt-end ligase and methods of use |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108129571A (zh) * | 2017-12-25 | 2018-06-08 | 上海捷瑞生物工程有限公司 | Taq DNA连接酶融合蛋白 |
-
2018
- 2018-12-17 CN CN201880099747.3A patent/CN113166270A/zh active Pending
- 2018-12-17 WO PCT/CN2018/121545 patent/WO2020124319A1/zh active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102597006A (zh) * | 2009-09-16 | 2012-07-18 | 梅西大学 | 融合多肽以及其应用 |
| US20140273102A1 (en) * | 2013-03-15 | 2014-09-18 | Theranos, Inc. | Thermostable blunt-end ligase and methods of use |
Non-Patent Citations (2)
| Title |
|---|
| ROBERT H WILSON ET AL.: "Engineered DNA ligases with improved activities in vitro", 《PROTEIN ENG DES SEL.》 * |
| 刘明珠等: "修饰的pfu酶与T7ssb蛋白在聚合酶链式反应中的应用", 《基因组学与应用生物学》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116004681A (zh) * | 2022-08-15 | 2023-04-25 | 南京诺唯赞生物科技股份有限公司 | 一种提高topo克隆中载体连接效率的方法及试剂盒 |
| CN116004681B (zh) * | 2022-08-15 | 2023-08-29 | 南京诺唯赞生物科技股份有限公司 | 一种提高topo克隆中载体连接效率的方法及试剂盒 |
| CN115896047A (zh) * | 2022-12-12 | 2023-04-04 | 南京诺唯赞生物科技股份有限公司 | 重组t4 dna连接酶突变体、融合蛋白及其应用 |
| CN115896047B (zh) * | 2022-12-12 | 2023-06-16 | 南京诺唯赞生物科技股份有限公司 | 重组t4 dna连接酶突变体、融合蛋白及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020124319A1 (zh) | 2020-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3957723A2 (en) | Engineered ligase variants | |
| US10883091B2 (en) | DNA polymerase variant and application thereof | |
| CN113166270A (zh) | 融合蛋白及其应用 | |
| CN113512541B (zh) | 一种新型磷酸化腺苷酰化酶及其制备方法与应用 | |
| CN113785053B (zh) | 酶活性提高的逆转录酶及其应用 | |
| WO2018107521A1 (zh) | T4多聚核苷酸激酶重组酶及其制备方法、表达基因、表达载体以及宿主细胞 | |
| EP3105254B1 (en) | Hybrid proteins and uses thereof | |
| CN114262697B (zh) | 融合Bsu DNA聚合酶和Bsu DNA聚合酶突变体及其基因、质粒、基因工程菌 | |
| EP0614982A1 (en) | Recombinant vector for the exocellular preparation of single chain antibodies expressed in bacillus subtilis | |
| CN114829593B (zh) | 嵌合dna聚合酶及其应用 | |
| CN113774039B (zh) | 重组型dna聚合酶及其应用 | |
| EP1981978B1 (en) | Affinity polypeptide for purification of recombinant proteins | |
| CN114230644A (zh) | 一种gp32蛋白突变体、重组载体及其构建方法和应用 | |
| CN114457067B (zh) | 一种低成本快速去除dna合成中错误的方法 | |
| CN113930405B (zh) | 一种新型热稳定磷酸化和腺苷酰化一步法催化酶及其制备方法与应用 | |
| CN115011578B (zh) | 一种强化型m-mlv逆转录酶突变体及其应用 | |
| CN117187210B (zh) | 一种突变型Bst DNA聚合酶大片段及其制备方法 | |
| CN118222537B (zh) | 性能提升的Taq DNA聚合酶突变体及其制备方法和应用 | |
| EP4455279A1 (en) | Dna polymerase mutant and use thereof | |
| CN116926039A (zh) | 反转录酶HIV p66突变体及其应用 | |
| CN117587041A (zh) | 重组尿酸酶及其制备方法和应用 | |
| CN116515781A (zh) | 磷酸甘油氧化酶及其突变体、制备方法和应用 | |
| CN116622744A (zh) | 重组末端脱氧核苷酸转移酶的制备方法和应用 | |
| CN116926034A (zh) | 重组肌酸激酶同工酶及其制备方法和应用 | |
| CN118222536A (zh) | phi29 DNA聚合酶突变体及其制备方法与应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210723 |
|
| RJ01 | Rejection of invention patent application after publication |